UA95458C2 - Вакцина против pcv-2 у mda-положительных поросят - Google Patents

Вакцина против pcv-2 у mda-положительных поросят

Info

Publication number
UA95458C2
UA95458C2 UAA200803112A UAA200803112A UA95458C2 UA 95458 C2 UA95458 C2 UA 95458C2 UA A200803112 A UAA200803112 A UA A200803112A UA A200803112 A UAA200803112 A UA A200803112A UA 95458 C2 UA95458 C2 UA 95458C2
Authority
UA
Ukraine
Prior art keywords
pcv
vaccine
orf
protein
mda positive
Prior art date
Application number
UAA200803112A
Other languages
English (en)
Ukrainian (uk)
Inventor
Франк Руринк
Вунсел Питер Ван
Original Assignee
Интервет Интернешонал Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35482131&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA95458(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Интервет Интернешонал Б.В. filed Critical Интервет Интернешонал Б.В.
Publication of UA95458C2 publication Critical patent/UA95458C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
UAA200803112A 2005-09-09 2006-09-08 Вакцина против pcv-2 у mda-положительных поросят UA95458C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05108299 2005-09-09

Publications (1)

Publication Number Publication Date
UA95458C2 true UA95458C2 (ru) 2011-08-10

Family

ID=35482131

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200803112A UA95458C2 (ru) 2005-09-09 2006-09-08 Вакцина против pcv-2 у mda-положительных поросят

Country Status (14)

Country Link
US (2) US20080248061A1 (ru)
EP (1) EP1926496B1 (ru)
JP (1) JP5106398B2 (ru)
KR (1) KR101347503B1 (ru)
CN (1) CN101277717A (ru)
AU (1) AU2006289102C1 (ru)
BR (1) BRPI0615862A2 (ru)
CA (1) CA2620727C (ru)
DK (1) DK1926496T3 (ru)
ES (1) ES2425228T3 (ru)
PL (1) PL1926496T3 (ru)
RU (1) RU2389506C2 (ru)
UA (1) UA95458C2 (ru)
WO (1) WO2007028823A1 (ru)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE025537T2 (en) * 2004-12-30 2016-05-30 Boehringer Ingelheim Vetmedica Inc PCV2-immunogenic compositions and methods for preparing such compositions
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
EP1968630B1 (en) 2005-12-29 2018-01-24 Boehringer Ingelheim Vetmedica, Inc. Multivalent pcv2 immunogenic compositions
MX338626B (es) 2005-12-29 2016-04-26 Boehringer Ingelheim Vetmed Uso de una composicion inmunogenica de pcv2 para producir los sintomas clinicos en cerdos.
EP2859900A1 (en) 2006-12-11 2015-04-15 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
JP5200223B2 (ja) 2006-12-15 2013-06-05 ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド Ｐｃｖ２抗原によるブタの処置
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
KR20100113582A (ko) 2008-01-23 2010-10-21 베링거잉겔하임베트메디카인코퍼레이티드 Ｐｃｖ2 마이코플라즈마 히오뉴모니에 면역원성 조성물 및 당해 조성물의 생산 방법
TWI449533B (zh) * 2008-04-18 2014-08-21 Intervet Int Bv 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）、豬肺炎黴漿菌（Ｍｙｃｏｐｌａｓｍａ ｈｙｏｐｎｅｕｍｏｎｉａｅ）及豬環狀病毒（Ｐｏｒｃｉｎｅ ｃｉｒｃｏ ｖｉｒｕｓ）用疫苗
TWI551295B (zh) 2008-04-18 2016-10-01 英特威特國際股份有限公司 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）用疫苗
AR078253A1 (es) 2009-09-02 2011-10-26 Boehringer Ingelheim Vetmed Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
CN101875941A (zh) * 2010-03-09 2010-11-03 胡文锋 一种人工改造合成的dORF2art基因及其编码的蛋白质
CA2804604C (en) 2010-07-08 2023-10-03 United Biomedical, Inc. Designer peptide-based pcv2 vaccine
CN101920012B (zh) * 2010-07-22 2012-12-12 普莱柯生物工程股份有限公司 利用家蚕生物反应器生产猪圆环病毒2型重组衣壳蛋白亚单位疫苗的方法及其产品
WO2012076623A1 (en) 2010-12-08 2012-06-14 Intervet International B.V. A method to quantify the amount of a biological substance in a sample and a kit for performing the method
EP2564869A1 (en) * 2011-09-02 2013-03-06 Ceva Sante Animale Synthetic capsid proteins and uses thereof
CN102352347A (zh) * 2011-10-14 2012-02-15 浙江诺倍威生物技术有限公司 Pcv2重组杆状病毒构建及其亚单位疫苗制备方法
CN102517331A (zh) * 2011-12-26 2012-06-27 武汉中博生物股份有限公司 一种猪圆环病毒2型亚单位疫苗及其制备方法和其应用
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
UA114504C2 (uk) * 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
CN102978232B (zh) * 2012-08-23 2014-07-16 郑州后羿制药有限公司 一种IPTG诱导猪圆环病毒2型重组Cap蛋白表达的方法
BR102013001893B1 (pt) 2013-01-25 2022-01-25 Fundação De Amparo À Pesquisa Do Estado De Minas Gerais - Fapemig Antígenos recombinantes do porcine circovirus 2 (pcv-2) para formulações vacinais, kit de diagnóstico e uso
ES2882374T3 (es) 2013-05-08 2021-12-01 Pharmgate Biologics Inc Vacuna para PCV2 y micoplasma
KR101527832B1 (ko) * 2013-05-28 2015-06-11 대한민국 돼지써코바이러스 2형(pcv2)의 orf2 재조합 유전자, 전달 벡터, 재조합 배큘로바이러스, 돼지써코바이러스 2형(pcv2) 재조합 캡시드 단백질 및 그의 제조방법
EP3049106A1 (en) * 2013-09-25 2016-08-03 Zoetis Services LLC Pcv2b divergent vaccine composition and methods of use
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
US9505808B2 (en) 2013-10-02 2016-11-29 Boehringer Ingelheim Vetmedica, Inc. PCV2 ORF2 protein variant and virus like particles composed thereof
CN104548083B (zh) * 2013-10-22 2019-05-07 洛阳赛威生物科技有限公司 一种疫苗组合物及其制备方法和应用
JP6488304B2 (ja) 2013-12-03 2019-03-20 インターベット インターナショナル ベー． フェー． ローソニア・イントラセルラリス（ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）及びブタサーコウイルス（ｐｏｒｃｉｎｅ ｃｉｒｃｏｖｉｒｕｓ）２に対するワクチン
ES2771899T3 (es) 2013-12-03 2020-07-07 Intervet Int Bv Vacuna contra circovirus porcino de tipo 2
JP6648138B2 (ja) * 2014-12-11 2020-02-14 インターベット インターナショナル ベー． フェー． 即時使用型ＰＣＶ２／Ｍ．ハイオ（Ｍ．ｈｙｏ）混合ワクチンのための工程
WO2017162727A1 (en) 2016-03-23 2017-09-28 Intervet International B.V. A combination vaccine against pcv2 and prrs virus infection comprising albumin
EP3432920A1 (en) 2016-03-23 2019-01-30 Intervet International B.V. A vaccine for intradermal application against pcv2 and prrs virus infection
CN108697782A (zh) 2016-03-23 2018-10-23 英特维特国际股份有限公司 针对pcv2病毒和猪肺炎支原体感染的组合疫苗
CN105785037B (zh) * 2016-03-30 2017-09-19 中国农业科学院兰州兽医研究所 猪圆环病毒2型抗体快速检测层析试纸条及制备方法
US11311614B2 (en) 2017-04-13 2022-04-26 Intervet Inc. Vaccines containing swine pathogens for associated non-mixed use
WO2019022463A2 (ko) * 2017-07-24 2019-01-31 (주)제이비바이오텍 면역원성시스템 및 이를 포함한 동물 백신
WO2019025519A1 (en) 2017-08-03 2019-02-07 Intervet International B.V. VACCINE COMPRISING GENOTYPE 2B PCV2 ORF2 PROTEIN
BR112020007498A2 (pt) 2017-10-17 2020-10-06 Intervet International B.V. expressão recombinante da proteína orf2 de pcv2b em células de insetos
CN119488586A (zh) 2018-03-26 2025-02-21 勃林格殷格翰动物保健美国有限公司 制备免疫原性组合物的方法
US20220323567A1 (en) 2019-09-12 2022-10-13 Intervet Inc. Combination vaccine for intradermal administration
CA3176154A1 (en) 2020-04-20 2021-10-28 Maarten Hendrik Witvliet A combination of vaccines to prophylactically treat a pig
WO2022090357A1 (en) 2020-10-29 2022-05-05 Intervet International B.V. Combination vaccine for protecting swine against various disorders
EP4704977A1 (en) 2023-05-03 2026-03-11 Boehringer Ingelheim Vetmedica GmbH Immunogenic composition useful for self-administration by pigs
CN121463956A (zh) 2023-05-03 2026-02-03 勃林格殷格翰动物保健有限公司 诱导免疫应答的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE115862T1 (de) * 1989-02-04 1995-01-15 Akzo Nobel Nv Tocole als impfstoffadjuvans.
ATE199022T1 (de) * 1996-10-09 2001-02-15 Akzo Nobel Nv Europäische vakzinstämme des fortplanzungs- atmungs-syndromsvirus des sweins (prrsv)
AUPO856097A0 (en) * 1997-08-14 1997-09-04 Commonwealth Scientific And Industrial Research Organisation Vector
US6517843B1 (en) * 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
US20040062775A1 (en) * 1997-12-05 2004-04-01 Agence Francaise De Securite Sanitaire Des Aliments Circovirus sequences associated with piglet weight loss disease (PWD)
FR2772047B1 (fr) * 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
US7276353B2 (en) * 2001-12-12 2007-10-02 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US7691368B2 (en) * 2005-04-15 2010-04-06 Merial Limited Vaccine formulations

Also Published As

Publication number Publication date
KR20080042159A (ko) 2008-05-14
CN101277717A (zh) 2008-10-01
PL1926496T3 (pl) 2014-02-28
AU2006289102C1 (en) 2017-11-30
JP2009507811A (ja) 2009-02-26
KR101347503B1 (ko) 2014-01-02
EP1926496A1 (en) 2008-06-04
CA2620727C (en) 2015-06-16
AU2006289102B2 (en) 2011-12-15
RU2008113763A (ru) 2009-10-20
CA2620727A1 (en) 2007-03-15
EP1926496B1 (en) 2013-06-26
DK1926496T3 (da) 2013-09-30
ES2425228T3 (es) 2013-10-14
US20110064765A1 (en) 2011-03-17
US8008001B2 (en) 2011-08-30
BRPI0615862A2 (pt) 2011-05-31
RU2389506C2 (ru) 2010-05-20
WO2007028823A1 (en) 2007-03-15
AU2006289102A1 (en) 2007-03-15
JP5106398B2 (ja) 2012-12-26
US20080248061A1 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
UA95458C2 (ru) Вакцина против pcv-2 у mda-положительных поросят
UA99708C2 (ru) Одноразовая доза поливалентной комбинированной вакцины, которая включает антиген цирковируса свиней типа 2
WO2007117303A3 (en) Combination vaccine comprising an attenuated bovine viral diarrhea virus
EA200801275A1 (ru) Стабилизированные составы карбоната лантана
MY152149A (en) Prevention and treatment of sub-clinical pcvd
IL155283A0 (en) Adjuvant composition comprising an immunostimulatory oligonucleotide and a tocol
MXPA06005639A (es) Adyuvante antimicrobiano.
MX2010008468A (es) Acidos nucleicos de la formula (i) (nug1xmgnnv)a y derivados de los mismos como un agente/adyuvante inmunoestimulante.
WO2007054279A3 (en) Cyclic-dinucleotides and its conjugates as adjuvants and their uses in pharmaceutical compositions
UA100502C2 (ru) Лечение prdc с применением антигена pcv2
WO2007095976A3 (de) Adjuvanz in form einer lipid-modifizierten nukleinsäure
BR112012006252A2 (pt) "formas cristalinas de abt-263 e solvatos para o uso no tratamento de doenças relacionadas á proteína bcl-2".
NO20082376L (no) Farmasoytiske sammensetninger
PL2054431T3 (pl) Konformery adhezyn bakteryjnych
TW200501965A (en) Highly pure fondaparinux sodium composition,process for preparing said composition and pharmaceutical compositions containing it as active principle
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
WO2006089114A3 (en) Methods and compositions for treating an anthrax toxin mediated condition
MX2010004899A (es) Conjugados de neurturina novedosos para uso farmaceutico.
ATE479440T1 (de) Virusstämme und zusammensetzungen des prrs- syndroms (porcine reproductive und respiratory syndrome) von schweinen
PL1965809T3 (pl) Kompozycje do poprawiania zdrowia jelit i użytkowości zwierząt zawierające beta-glukany i alfa-fukany
TW200511999A (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
WO2006137938A3 (en) Antibody fragments for protection from pathogen infection and methods of use thereof
TW200609200A (en) Preparation of levalbuterol hydrochloride
WO2007077318A3 (fr) Utilisation d'un extrait peptidique de riz en tant qu'agent actif inducteur de la synthese des proteines sirt dans les cellules de la peau
UA95299C2 (ru) Профилактический или терапевтический агент против вирусного заболевания, вызванного вирусом гепатита с